vendredi 7 décembre 2018

Onco Actu du 7 décembre 2018

3. Prévention

Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers - A Complex Discussion [JAMA]

4. Dépistage, diagnostic et pronostic

Dr. Lisa Schwartz, 55, Is Dead; Warned of Unnecessary Treatments [NY Times]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products [FDA]

FDA Proposes New Steps to Advance Clinical Testing to Deliver New Cures [FDA]

4.10 Dép., diag. & prono. - Poumon

Lung cancer screening part 2: research into detection technology could lead to better tests [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

How DNA Companies Like Ancestry And 23andMe Are Using Your Genetic Data [Forbes]

The 100,000 Genomes Project has finished: what were the challenges and what comes next? [Institute of Cancer Research]

5. Traitements

The Promise—and Heartbreak—of Cancer Genomics [Wired]

5.1 Traitements - Pré-clinique

New hope for treating “chemo brain,” with a side of the joy of science [Stanford Medicine]

How does chemo brain work? One cancer drug might interfere with brain signaling [Science]

5.10 Traitements - Essais

Billions spent, but AbbVie can't catch a break with Rova-T as it cans SCLC trial [FierceBiotech]

AbbVie's Rova-T hits yet another setback [BiopharmaDive]

Worse Than Useless [In the Pipeline]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

NICE recommends a CAR T-cell therapy for adults with some types of non-Hodgkin lymphoma [NICE]

5.12.5 Immunothérapies - Pharma

Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer [AstraZeneca]

AstraZeneca’s prized Imfinzi/tremelimumab combo fails again — this time in head and neck cancer [EndPoints]

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study [Reuters]

5.12.6 Immunothérapies - AMM

FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer [Roche]

Roche's lung cancer combo treatment wins FDA approval [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves Three New Treatments for AML [Cancer Research Catalyst]

5.7.1 SABCS-communiqués

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium [Puma]

Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium [Puma]

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium [Puma]

Myriad Validates Polygenic Score to Predict Breast Cancer Risk in Women of Hispanic Ancestry Who Test Negative for Hereditary Cancer Mutations [Myriad]

5.7.2 SABCS-divers

Liquid Biopsies in SOLAR-1 Trial Predict Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer [AACR]

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses [Novartis]


Black Women Have Worse Breast Cancer Outcomes Despite Receiving Similar Treatment as White Women [AACR]

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence [AACR]

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer [AACR]

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients [AACR]

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH [AACR]

5.7.4 SABCS-essais

Major EORTC trial presented at San Antonio Breast Cancer Conference: 10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node [EORTC]

6.12 Ethique

Top cancer center’s business deals created a web of conflicts, say ethics experts [STAT]

6.5 Médecines alternatives/complémentaires

The case of Omer Ahmetovic: Naturopathy, cancer, tragedy, and homicide [Respectful Insolence]

6.6 Publications

ORCID Open Letter - Funders [ORCID]

6.7 DMP, Big Data & applis

What specific protections apply to health-related, genetic, or biometric data? [Global Alliance for Genomics and Health]

6.7.1 IA/bioinformatique

Artificial intelligence in pharma, health care: at the crossroads of hype and reality [STAT]